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Background: Escitalopram is a selective serotonin reuptake inhibitor, widely used in the treat-
ment of affective disorders. The purpose of this study was to examine its safety and tolerability, 
as mono- versus augmentative therapy, in a group of patients with affective disorders.
Materials and methods: The sample consisted of 131 patients suffering from different affec-
tive disorders, including major depressive disorder, bipolar disorder, and generalized anxiety 
disorder, who received escitalopram for at least 4 weeks. Data were analyzed on the basis of 
mono- versus augmentative therapy, as well as age, gender, mean daily dosage, and patterns 
of combination therapy.
Results: Sixty-seven (51.1%) patients were treated with monotherapy (mean dose of 
11.76 mg/day) and 64 (48.9%) with augmentative escitalopram (mean dose of 12.81 mg/day). 
The mean duration of escitalopram treatment was 14 months. The most frequently combined 
compounds were: other antidepressants (36.5%), mood stabilizers (33.4%), and atypical antip-
sychotics (30.1%). Side effects were reported in 5.3% of the total sample and the most common 
were insomnia (2.3%), nausea (2.3%), and dizziness (0.8%). No significant difference, in terms 
of tolerability, in mono- versus augmentative therapy groups was found. In addition, neither 
age nor gender was significantly correlated with a greater presence of side effects. Finally, no 
significant correlation between dosage and side effects was observed.
Conclusion: Over a 14-month observation period, escitalopram, either as monotherapy or an 
augmentative treatment, was found to be well tolerated in a large sample of patients with affec-
tive disorders, with an overall low rate of side effects.
Keywords: affective disorders, escitalopram, tolerability, monotherapy, augmentative 
therapy
Introduction
Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is the S enantiomer of 
citalopram, a racemic mixture of the R and S enantiomers, in a 1:1 ratio.1 The two ste-
reoisomers markedly differ in potency for the inhibition of neuronal serotonin uptake, 
with escitalopram being more potent than the R enantiomer. The S enantiomer, in fact, 
seems to be associated with greater antidepressant activity, whereas the R enantiomer 
has been found to compete with the S enantiomer on the serotonin transporters, with 
lower affinity.2
Escitalopram is currently approved for the treatment of major depressive disorder 
(MDD). In addition, in many countries of the European Union, it is indicated for the 
treatment of some anxiety disorders, like panic disorder, social anxiety disorder, gen-
eralized anxiety disorder (GAD), and obsessive-compulsive disorder.3 The compound 
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is licensed for use at doses up to 20 mg/day, while there are 
few data supporting its use at higher doses.4,5
In terms of tolerability, common side effects 
( incidence $ 5%) of escitalopram, occurring during the 
first 8 weeks of treatment (and more frequently than placebo), 
were represented by nausea, insomnia, fatigue, diarrhea, diz-
ziness, dry mouth, somnolence, and ejaculation failure.3 With 
respect to cardiovascular safety, a dose-dependent increase of 
QT interval and ventricular arrhythmias, including Torsade 
de Pointes, have been recently reported.6
Actually, the short-term side effects profile of escitalo-
pram was found to be similar to citalopram and significantly 
better than venlafaxine.3,7 A limited number of patients 
were found to discontinue escitalopram due to side effects, 
although this was significantly fewer than those who discon-
tinued when on paroxetine or venlafaxine.7,8 In general, the 
incidence of reported side effects tended to decrease over 
time, even though related withdrawals, occurring in the early 
stages of double-blind treatment, imply that patients, who 
continue with longer treatment, are likely those with good 
tolerability at the beginning.3 Furthermore, long-term use 
of escitalopram in depressive and anxiety disorders did not 
result in the emergence of side effects, which had not been 
seen during acute treatment.9
To date, despite several studies evaluating the acute and 
long-term tolerability of the molecule in patients with affec-
tive disorders, few data comparing the safety and tolerability 
of escitalopram in mono- versus augmentative therapy are 
available, particularly for longer observation periods. Such an 
issue, however, seems to be of relevant clinical importance, 
reflecting real clinical practice among patients with comorbid 
medical and psychiatric disorders, who are on concomitant 
polytherapies, and who are of different age groups.
Therefore, the aim of the present study is to naturalisti-
cally assess the safety and tolerability of escitalopram and 
related patterns of prescription (ie, main psychiatric diagno-
sis, medical and psychiatric comorbidities, and prescription 
in different age groups) in a large sample of patients with 
affective disorders, focusing on the comparison between 
mono- versus augmentative therapy.
Methods
The sample consisted of 131 outpatients attending the Mood 
Disorder Clinic and related community services at the Depart-
ment of Psychiatry of the University of Milan between 2010 
and 2011. Eligible patients were adult subjects who were 
diagnosed with mood and/or anxiety disorders (eg, MDD, 
BD, and GAD), according to the Diagnostic and Statistical 
Manual (DSM)-IV-TR criteria.10 If a comorbid disorder was 
present, the affective disorder had to be the primary condition 
(ie, causing the most significant distress and dysfunction), and 
it had to provide the primary motivation to seek treatment.
Diagnoses were performed by trained psychiatrists 
through the administration of the Structured Clinical Interview 
for DSM Axis I (SCID-I)11 and Axis II (SCID-II).12 The diag-
nostic evaluation was additionally completed in order to better 
quantify the severity of the disorder, with the administration 
of the following psychometric scales: the Hamilton Rating 
Scale for Depression,13 the Hamilton Anxiety Rating Scale,14 
the Montgomery–Asberg Rating Scale for Depression,15 and 
the Clinical Global Impression scales.16
Recruited patients had to be older than 18 years, of either 
gender, and treated with escitalopram for at least 1 month. 
Escitalopram was prescribed either as sole therapy or as 
an augmentative agent. After obtaining patients’ written 
informed consent, clinical and demographic variables were 
collected, including: age, gender, age at onset, primary 
diagnosis, family history for mental disorders, psychiatric 
and medical comorbidity, mean daily dosage and overall 
duration of escitalopram, combined therapy, adverse events, 
and side effects.
The assessment of safety and tolerability represented the 
primary study aim, and such aspects were assessed at each 
monthly visit after baseline, using spontaneously reported 
events and rates of discontinuation for adverse events. In 
addition, patients were specifically required to report the 
occurrence of cardiovascular symptoms such as palpitations, 
dizziness, syncope, or seizures developed during treatment. 
In such cases, a cardiac evaluation including electrocardi-
ography (ECG) was planned in order to exclude malignant 
arrhythmias.
At the end of the observation period – lasting from a 
minimum of 4 weeks to several months – patients were 
divided in two groups, according to receiving either mono- 
or augmentative therapy. Patients included in the second 
group were additionally divided into different subgroups 
based on the compound escitalopram was augmented to (eg, 
mood stabilizers, other antidepressants [SSRIs, serotonin–
norepinephrine reuptake inhibitors, tricyclic antidepressants], 
typical and atypical antipsychotics), and demographic and 
clinical variables were compared using one-way analyses of 
variance for continuous variables, and χ2 tests for categorical 
ones. Post-hoc tests (Bonferroni) were additionally performed 
to assess between-group differences. For all the analyses, the 
level of statistical significance was set at 0.05. All the statis-
tical analyses were performed using the Statistical Package 
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for the Social Sciences for Windows software (version 17.0; 
SPSS Inc., Chicago, Illinois, USA).
Results
The study sample consisted of 49 males (37.4%) and 
82 females (62.6%), with a mean age of 53.8 ± 15.16 years 
and a mean age at onset of 39.25 ± 16.2 years. Fifty-three 
(40.4%) patients were older than 60 years old. Demographic 
and clinical variables of the total sample are summarized in 
Table 1. The most common diagnoses were MDD (n = 66, 
50.4%), BD (n = 21, 16%), and GAD (n = 12, 9.2%).
Sixty-seven patients (51.1%) received escitalopram 
as sole therapy (mean dosage of 11.76 mg/day), whereas 
64 patients (48.9%) were in the augmentation group (mean 
dosage of 12.81 mg/day). The group on polytherapy had, 
understandably, more severe clinical features, as indicated 
by a longer duration of illness (t = 2.983; P = 0.005) and 
higher rates of psychiatric comorbidity (t = 3.345; P = 0.001). 
The mean duration of escitalopram treatment did not differ 
between the two groups, ranging from 12.5 to 16 months.
Statistical analysis revealed no significant differences in 
terms of the escitalopram daily dosage between the mono- 
and augmentative therapy groups.
The main associated treatments were represented by 
other antidepressants (36.5%), mood stabilizers (33.4%), and 
atypical antipsychotics (30.1%). Side effects were reported 
in 5.3% of the total sample and included: insomnia (2.3%), 
nausea (2.3%), and dizziness (0.8%), which were the most 
frequently observed ones. Statistical analysis showed no 
significant differences in terms of tolerability in the mono-
therapy group versus the augmentative therapy group. Side 
effects were mild and no patient had to discontinue therapy 
because of adverse events. No cardiovascular symptoms were 
reported during the study and it was not necessary to perform 
any ECG monitoring. Side effect rates of the total sample 
and the related subgroups are reported in Table 2.
Table 1 Demographic and clinical variables of the study sample
Variables Total sample (n = 131) Monotherapy (n = 67) Polytherapy (n = 64)
Gender Males n = 49 (37.4%) 
Females n = 82 (62.6%)
Males = 22 (33%) 
Females = 45 (67%)
Males = 27 (42%) 
Females = 37 (58%)
Age (years) 53.8 ± 15.16 51.79 ± 15.78 55.94 ± 14.29
Age at onset (years) 39.25 ± 16.2 41.46 ± 17.33 36.74 ± 14.58
Duration of illness (months) 176.6 ± 171.9 138.11 ± 129.32* 215.56 ± 169.43*
Most common diagnoses 
 Major depressive disorder 
 Bipolar disorder 
 Generalized anxiety disorder
 
n = 66 (50.4%) 
n = 21 (16%) 
n = 12 (9.2%)
 
n = 39 (58%) 
n = 4 (6%) 
n = 8 (12%)
 
n = 27 (42%) 
n = 18 (28%) 
n = 4 (6%)
Family history of psychiatric disorders n = 57 (43.5%) n = 33 (49%) n = 46 (72%)
Psychiatric comorbidity 
 Absent 
 Generalized anxiety disorder 
 Alcohol/substance abuse 
 Major depressive disorder
 
n = 52 (44.4%) 
n = 21 (17.9%) 
n = 18 (15.4%) 
n = 8 (6.8%)
 
n = 34 (51%)** 
n = 8 (12%) 
n = 9 (13%) 
n = 3 (4%)
 
n = 18 (28%)** 
n = 13 (20%) 
n = 9 (14%) 
n = 5 (8%)
Medical comorbidity 
 Absent 
 hypertension 
 Cardiovascular disorders 
 Cancer
 
n = 45 (40.5%) 
n = 9 (8.1%) 
n = 6 (5.4%) 
n = 6 (5.4%)
 
n = 27 (40%) 
n = 6 (9%) 
n = 3 (4%) 
n = 3 (4%)
 
n = 18 (28%) 
n = 3 (5%) 
n = 3 (5%) 
n = 3 (5%)
Mean dose of escitalopram (mg) 12.28 ± 3.25 11.76 ± 4.58 12.81 ± 6.25
Combined treatments 
 Mood stabilizers 
 Other antidepressants 
 Atypical antipsychotics
 
n = 19 (15%) 
n = 10 (8%) 
n = 19 (15%)
 
– 
– 
–
 
n = 19 (30%) 
n = 10 (16%) 
n = 19 (30%)
Mean duration of escitalopram  
treatment (months)
14.34 ± 12.42 16.02 ± 15.24 12.47 ± 11.51
Side effects 
Insomnia 
Nausea 
Dizziness
n = 7 (5.3%) 
n = 3 (2.3%) 
n = 3 (2.3%) 
n = 1 (0.8%)
n = 4 (6%) 
n = 1 (1%) 
n = 2 (3%) 
n = 1 (1%)
n = 3 (5%) 
n = 2 (3%) 
n = 1 (1%) 
n = 0 (0%)
Notes: *Duration of illness: t = 2.983; P = 0.005; **rates of psychiatric comorbidity: t = 3.345; P = 0.001. Standard deviations for continuous variables and percentages for 
dichotomous ones are shown in brackets.
Abbreviation: n, number.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
207
Escitalopram tolerability in patients with affective disorders
Neuropsychiatric Disease and Treatment 2013:9
Table 2 Side effect rates in the total sample and among related subgroups
Side effects Total sample 
n = 7 (5.3%)
Monotherapy 
n = 4 (6%)
Polytherapy 
n = 3 (5%)
Type of combined treatment 
n = 3 (5%)
Insomnia n = 3 (2.3%) n = 1 (1%) n = 2 (3%) Typical antipsychotics
Nausea n = 3 (2.3%) n = 2 (3%) n = 1 (1%) TCAs
Dizziness n = 1 (0.8%) n = 1 (1%) n = 0 (0%) None
Abbreviations: n, number; TCA, tricyclic antidepressants.
The statistical analysis showed no significant correlation 
between side effects and age (Phi = 0.150; χ2 = 0.08), com-
bined therapy (Phi = 0.029; χ2 = 0.74), and gender (Phi = 0.04; 
χ2 = 0.62). Furthermore, no statistically significant asso-
ciations were reported between increasing dosages and the 
amount of side effects experienced (t = 3.21; P = 0.08).
Discussion
Escitalopram was found to be well tolerated overall in a 
large sample of patients with affective disorders, both as a 
monotherapy and as augmentative treatment, as well as in 
older patients. In fact, a minor rate of subjects (5.3%) showed 
side effects, with insomnia, nausea, and dizziness being the 
most common ones. Side effects were mild and transient, 
and no discontinuation of therapy due to tolerability issues 
occurred in the sample over the whole observation period. 
From this perspective, the reported results seem to be of 
particular clinical interest given that, on average, the duration 
of treatment lasted more than 1 year in the whole sample and 
across the related subgroups.
The cardiovascular safety of escitalopram is an important 
issue to consider. Recent data from the literature showed that 
escitalopram may affect the QTc interval, likely through a dose-
dependent mechanism.17 Recently, Hanash et al18 examined the 
CV safety of 1-year of treatment with escitalopram, compared 
with placebo, in patients with recent acute coronary syndrome, 
supporting the safety and favorability profile of the compound 
in such patients. In the present study, no cardiovascular side 
effects were reported, even though it needs to be specified that 
the study methods did not include routine ECG monitoring.
In clinical practice, augmentative and combination thera-
pies are considered valid strategies to treat partial response 
or lack of response to antidepressant monotherapy, even 
though such an approach may lead to an increase in side 
effects, adverse effects, drug interactions and, ultimately, 
reduced compliance.19
Data from the present study seem to suggest that esci-
talopram may be safely used in combination with other 
compounds (eg, mood stabilizers, other antidepressants, and 
antipsychotics). On the one hand, such results may not support 
what is  generally observed in clinical practice, with combined 
treatments resulting in higher frequency of side effects when 
compared to monotherapies. On the other hand, they seem to 
support a particularly favorable tolerability for selective anti-
depressants, like escitalopram. Present findings are, moreover, 
consistent with a recent meta-analysis of Rocha et al,20 who 
reviewed studies assessing the effect of the combination of anti-
depressants in MDD. Mirtazapine plus SSRIs, and tricyclic anti-
depressants plus SSRIs resulted in superior effects than SSRIs 
alone in obtaining remission, or achieving both remission and 
response, respectively. Consistently with the present report, the 
authors did not find any difference between the combined and 
monotherapy groups in terms of drop-out rates due to adverse 
effects. Such results were seen as supportive of the greater 
efficacy of antidepressant combinations versus monotherapies, 
with no significant decrease in tolerability.20 However, it needs 
to be specified that the review by Rocha et al20 solely focused 
on the acute treatment of MDD and, moreover, on the combina-
tion of antidepressants, whereas our sample included patients 
with additional diagnoses as well, using different psychotropic 
compounds in their therapeutic regimen.
Other studies have assessed the long-term efficacy and tol-
erability of combination treatments. Rush et al,21 for instance, 
compared two antidepressant combinations with SSRI mono-
therapy to determine whether combination treatment produced 
higher remission rates in the acute phase (12 weeks) and after 
long-term treatment (7 months). Of note, they found that no 
combination therapy outperformed monotherapy. Moreover, 
the authors found that some combinations (eg, extended-
release venlafaxine plus mirtazapine, versus escitalopram plus 
placebo) may bring a higher risk of side effects.21
In the present study, the statistical analysis showed that 
age did not correlate with the presence of side effects. Such 
findings seem to be of clinical relevance, suggesting that the 
molecule might be used in the elderly without any additional 
specific concerns within the recommended therapeutic range. 
In addition, gender did not significantly correlate with side 
effects, suggesting the absence of gender-specific differences 
in the pharmacodynamic and pharmacokinetic profiles of 
the compound.
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Finally, the absence of a significant correlation between 
dosage and side effects seems to support a favorable toler-
ability profile for the molecule, which is consistent with the 
available literature.5,22,23 From this perspective, Wade et al5 
conducted an open-label, pilot study to investigate the effi-
cacy, safety, and tolerability of escitalopram in doses up to 
50 mg in MDD. In this study, doses up to 40 mg were gener-
ally well tolerated, whereas higher doses were more poorly 
tolerated. Furthermore, no unexpected safety issues arose 
from the use of higher doses, with only minor weight gain 
being observed, which did not appear to be dose related.5
In conclusion, the present study showed escitalopram 
to be safe and well tolerated in a large sample of patients 
with affective disorders, used either as sole or combination 
therapy, both in young and elderly people. The study was 
conducted with an open design and without a randomization 
process or a control group, so further long-term, double-blind 
randomized controlled studies are necessary to confirm the 
present results.
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